NCT03057795View on ClinicalTrials.gov

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

April 3, 2017

Primary Completion Date

January 30, 2021

Study Completion Date

March 25, 2026

Conditions
Classic Hodgkin LymphomaRecurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
Interventions
DRUG

Brentuximab Vedotin

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

55905

Mayo Clinic in Rochester, Rochester

77030

M D Anderson Cancer Center, Houston

91010

City of Hope Medical Center, Duarte

98109

Fred Hutchinson Cancer Research Center, Seattle

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER